Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that two studies of SL-401, a clinical stage therapeutic being developed in patients with myeloid malignancies, have also demonstrated preclinical activity against a variety of lymphoid malignancies and have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, CA from December 10-13, 2011.

One study demonstrates that SL-401 potently inhibits the growth of several Hodgkin's lymphoma (HL) cell lines, and has activity against mantle cell lymphoma (MCL), a non-Hodgkin's lymphoma, as well as T-cell acute lymphoblastic leukemia (T-ALL) cell lines. The other study shows that SL-401 is cytotoxic against primary tumor cells obtained from patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare lymphoma with limited treatment options. These results indicate that further evaluation of SL-401 against lymphoid cancers is warranted.

Stemline and its collaborators from NYU Langone Medical Center, Scott and White Memorial Hospital, and the Institut National de la Sante et de la Recherche Medicale will present the posters.  

Owen O'Connor, MD, PhD, of NYU Langone Medical Center and a collaborator on these studies, noted: "Patients with recurrent lymphoid malignancies, in particular, Hodgkin's disease, have few viable treatment options. The initial efficacy data with SL-401 are exciting and we look forward to working with Stemline to further explore this agent in animal studies and beyond."

Ivan Bergstein, MD, CEO of Stemline, commented: "SL-401 is currently being developed in patients with myeloid malignancies. These new data provide an additional potential path forward in lymphoid cancers. We look forward to continuing our collaboration with Dr. O'Connor's group as we continue to pursue this opportunity."

Details on the abstracts selected for presentat
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Mo. From cell phones to cars and ... life. Scientists and technology companies constantly are seeking ... for the first time using a water-based solution, ... a long-lasting and more efficient nuclear battery that ... a reliable energy source in automobiles and also ...
(Date:9/16/2014)... BlueInGreen® , a water quality company ... dissolved gases into liquids, announced the addition of ... representative firm to its sales network. H2Flow will ... and wastewater applications in the Canadian provinces of ... 1992 and serves Quebec and Ontario markets for ...
(Date:9/16/2014)... Sept. 16, 2014  Donald Fresne, President and CEO of ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl (European ... at Inserm, the French institute of health and medical research. ... at the Curie Institute, Orsay, France , ...
(Date:9/16/2014)... 2014  The Council for Entrepreneurial Development (CED), ... the country, today released a mid-year update to ... It showed that in the first half ... startups in the technology, life science, advanced manufacturing ... a variety of sources. Significant investment in technology companies ...
Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... ... first private companies providing paternity and other ancestry testing in Germany, ... new German Genetic Diagnosis Act ("Gendiagnostikgesetz"): German legislation has passed several ... as well as paternity testing. The new Genetic Diagnosis Act, which ...
... ... may be asking how the billions poured into science R&D has helped stimulate our economy. ... just ended as their first branded year with new hires, new instruments and more business ... ...
... ON , Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences ... the Company that it may now enroll patients at US ... of its lead product, nimotuzumab. One of the two trials ... for curative treatment and being treated palliatively and the other ...
Cached Biology Technology:bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 2bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 3bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 4US Nanotechnology Instrument Manufacturer Proves the Success of R&D Stimulus 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 3YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 5
(Date:9/16/2014)... for the dinosaurs 66 million years ago decimated the ... extent than their deciduous peers, according to a study ... the journal PLOS Biology . , Applying ... fossilized leaves of angiosperms flowering plants excluding ... ecology of a diverse plant community thriving during a ...
(Date:9/16/2014)... the Keystone XL pipeline (KXL) would likely increase oil ... researchers surveyed by the non-profit organization Near Zero. The ... Climate Impact," and includes both supporters and opponents of ... oil sands could lead to significantly higher greenhouse gas ... markets respond. , "This report examines three main ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
Breaking Biology News(10 mins):Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Smoking and schizophrenia linked by alterations in brain nicotine signals 2
... shows that a "gatekeeper" protein plays an important role in ... C/EBP alpha, is normally abundantly expressed to help protect skin ... The NC State research shows, however, that the protein is ... Moreover, when the protein is inactivated in special lab mice ...
... JOLLA, CAThe seeds sprouting in your spring garden may still be ... finite energy pack contained within each seed. Once those resources are ... a "green" photosynthetic program. Researchers at the Salk Institute for Biological ... In a study published in the May 24, 2011, issue ...
... highly coveted technical capabilities as the observation of ... detection of low concentrations of biochemical agents and ... Researchers with the U.S. Department of Energy (DOE),s ... with researchers at the University of Stuttgart in ...
Cached Biology News:Lack of 'gatekeeper' protein linked to skin cancer 2It's not easy being green 2It's not easy being green 3Sharpening the nanofocus 2Sharpening the nanofocus 3Sharpening the nanofocus 4
... Extract Protein Array Kit is designed for ... The expression of a protein in an ... antibody. When the antibody binds the protein, ... chemiluminescent or fluorescent signal created by directly ...
... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
... mounting medium designed for the preservation ... especially recommended when using tracers containing ... can also be used with conventional ... Rhodamine (TMRITC) and Texas Red. Gel/Mount ...
...
Biology Products: